SOST and chronic kidney disease: While a few studies report that dialysis patients with high serum sclerostin levels have an improved survival rate and a decreased risk of cardiovascular mortality [125, 136, 137], there are also other reports showing a positive or no association of serum sclerostin with all-cause mortality [111, 138, 139] Until now, the association between levels of Wnt inhibitors and mortality in CKD is not well defined.